Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial.
- Author:
Wen-Yu YANG
1
,
2
;
Tian-Feng LIU
;
Xiao-Juan CHEN
;
Ye GUO
;
Ting LI
;
Ben-Quan QI
;
Fang LIU
;
Li-Xian CHANG
;
Min RUAN
;
Xiao-Ming LIU
;
Li ZHANG
;
Yao ZOU
;
Yu-Mei CHEN
;
Xiao-Fan ZHU
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. xfzhu1981@
2. com.
- Publication Type:Journal Article
- MeSH:
Child;
Granulocyte Colony-Stimulating Factor/therapeutic use*;
Humans;
Neutropenia;
Polyethylene Glycols;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*;
Prospective Studies;
Recombinant Proteins
- From:
Chinese Journal of Contemporary Pediatrics
2020;22(11):1172-1177
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the pharmacokinetic characteristics, clinical effect, and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in children with acute lymphoblastic leukemia (ALL).
METHODS:A prospective study was performed on children with ALL who cyclophosphamide, cytarabine, and 6-mercaptopurine were used for consolidation therapy. PEG-rhG-CSF (PEG-rhG-CSF group) or rhG-CSF (rhG-CSF group) was injected after chemotherapy. The plasma concentration of PEG-rhG-CSF was measured, and clinical outcome and safety were observed for both groups.
RESULTS:A total of 17 children with ALL were enrolled, with 9 children in the PEG-rhG-CSF group and 8 children in the rhG-CSF group. In the PEG-rhG-CSF group, the peak concentration of PEG-rhG-CSF was 348.2 ng/mL (range 114.7-552.0 ng/mL), the time to peak was 48 hours (range 12-72 hours), and the half life was 14.1 hours (range 11.1-18.1 hours). The plasma concentration curve of PEG-rhG-CSF was consistent with the mechanism of neutrophil-mediated clearance. Compared with the rhG-CSF group, the PEG-rhG-CSF group had a significantly shorter median time to absolute neutrophil count (ANC) recovery (P<0.05). There were no significant differences between the two groups in ANC nadir, incidence rate of febrile neutropenia, duration of grade IV neutropenia, incidence rate of infection, and length of hospital stay. No bone pain or muscle soreness was observed in either group (P>0.05).
CONCLUSIONS:The pharmacokinetic characteristics of PEG-rhG-CSF in children with ALL receiving consolidation chemotherapy are consistent with the mechanism of neutrophil-mediated clearance, with a short half life and fast recovery of ANC, and there are no significant differences in safety between PEG-rhG-CSF and rhG-CSF.
